Status:
COMPLETED
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Kidney Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
Eligibility Criteria
Inclusion
- Histologically documented RCC with metastases.
- Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to disease progression or unacceptable treatment-related toxicity
Exclusion
- Any prior systemic treatment for Renal Cell Carcinoma \[RCC\] other than 1 prior cytokine-based treatment regimen. Cytokine-based regimens containing thalidomide or an anti-angiogenesis agent are not allowed.
- Inability to take oral medication
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00076011
Start Date
October 1 2003
End Date
February 1 2007
Last Update
June 26 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Francisco, California, United States, 94115
2
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
3
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
4
Pfizer Investigational Site
New York, New York, United States, 10021